This bill lets the President negotiate and sign trade agreements with foreign countries to remove or reduce import duties and other limits on medical goods. "Medical goods" includes medical devices, drugs, and inputs for those products. Agreements would be with "trusted trade partners" that meet standards such as protecting intellectual property, following good regulatory practices, and keeping trade open during public health emergencies. Agreements can include duty cuts, regulatory cooperation, faster cross-border movement, access to government procurement, research collaboration, and exemptions from trade-restrictive measures during emergencies. The bill requires advance notice to Congress, regular reporting, consultations with committees and federal agencies (including the Trade Representative and HHS), formal review periods for Congress before an agreement takes effect, monitoring of partner compliance, and steps the President can take if a partner fails to comply.
If enacted, the law would create a process for the United States to make trade deals focused only on medical goods with selected partner countries. The stated goals are to make medical supplies more reliable, speed movement of those goods across borders, support research cooperation, and protect intellectual property used in medical products. For patients and health providers, the bill aims to reduce the risk of shortages by diversifying suppliers and easing trade steps. For manufacturers and researchers, it aims to promote regulatory cooperation and data flows and could change which foreign suppliers are favored in U.S. procurement.
No publicly available information.
The bill states that supporters believe the COVID-19 pandemic showed U.S. dependence on a narrow set of suppliers and that removing trade barriers with trusted partners will improve national security and public health. Supporters aim to diversify suppliers, protect intellectual property, speed cross-border movement of medical goods, promote regulatory cooperation, and encourage investment and research collaboration.
No publicly available information.